Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr Sampath on the Safety of Consolidative Radiotherapy Plus Osimertinib in Advanced EGFR-Mutant NSCLC

October 7th 2025

Sagus Sampath, MD, discusses the safety profile of consolidative radiotherapy administered in conjunction with osimertinib in advanced EGFR-mutant NSCLC

Exploring Sigvotatug Vedotin–Based Combinations in Advanced NSCLC

October 7th 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss the investigation of sigvotatug vedotin plus pembrolizumab in NSCLC.

Evaluation of Sigvotatug Vedotin Monotherapy in Previously Treated, Nonsquamous NSCLC

October 7th 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss the investigation of sigvotatug vedotin in nonsquamous NSCLC.

Managing Immune-Related AEs in NSCLC

October 7th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the management of immune-related adverse effects in advanced NSCLC.

How Cemiplimab Plus Chemo Has Affected First-Line NSCLC Management, Including Squamous Histology

October 7th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the impact of the FDA approval of cemiplimab plus chemotherapy in advanced NSCLC.

NICE Recommends First-Line Lorlatinib for Newly Diagnosed ALK+ NSCLC

October 7th 2025

Lorlatinib has received NICE’s recommendation for untreated advanced non–small cell lung cancer.

Streamlining Surgical Tissue Coordination for Biomarker Testing in Early-Stage NSCLC

October 7th 2025

Panelists discuss how multidisciplinary coordination and early communication between surgical, pulmonary, and oncology teams ensures adequate tissue procurement for molecular testing from the initial biopsy.

Integrating Biomarker Results Into Treatment Planning for NSCLC

October 7th 2025

Panelists discuss how to manage the waiting period for biomarker results while balancing urgency in curable patients, emphasizing the importance of tissue-based testing over liquid biopsies in early-stage disease.

Expanding Access to Biomarker Testing in Early-Stage NSCLC

October 7th 2025

Panelists discuss how surgeon-led ultrasound-guided biopsies can expedite care timelines and overcome barriers to guideline-concordant biomarker testing that still affects one-third of eligible patients.

Lung Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025

October 6th 2025

Check out this September recap of OncLive’s coverage of the top news and expert insights in lung cancer.

Five Under 5: Top Oncology Videos for the Week of 9/28

October 5th 2025

The top 5 OncLive TV videos of the week cover insights in lung cancer, and prostate cancer, myelofibrosis.

The OncFive: Top Oncology Articles for the Week of 9/28

October 4th 2025

The FDA clears maintenance lurbinectedin combination in lung cancer, T-DxD sBLA in HER2-positive breast cancer is accepted for review, and more.

Q4 2025: 10 FDA Decisions to Watch in the Realm of Oncology

October 3rd 2025

Here is your Q4 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for belantamab mafodotin, revumenib, sevabertinib, and more.

Emerging Role of Neoadjuvant Strategies in Limited-Stage SCLC

October 3rd 2025

Panelists discuss how preliminary neoadjuvant chemoimmunotherapy data showing high response rates and pathologic complete responses in limited-stage SCLC appears promising but requires larger studies and careful patient selection given the complexity of staging and surgical candidacy.

Identifying Patients Likely to Benefit From Immunotherapy Approaches

October 3rd 2025

Panelists discuss how while emerging biomarkers like inflamed subtypes and MHC class I expression show promise for predicting immunotherapy benefit, current clinical practice treats all patients with immunotherapy since the potential for exceptional responses cannot be reliably predicted.

FDA Approves Lurbinectedin Plus Atezolizumab as First-Line Maintenance Therapy for ES-SCLC

October 2nd 2025

The FDA approved lurbinectedin plus atezolizumab as first-line maintenance for ES-SCLC that has not progressed after frontline induction therapy.

Inside the Most Anticipated Lung Cancer Abstracts: What to Expect From ESMO 2025

October 2nd 2025

Ahead of the 2025 ESMO Congress, OncLive spoke with experts in lung cancer care to preview the most anticipated meeting abstracts.

Dr Lee on Disease-Free Survival Outcomes With Alectinib in ALK+ NSCLC

September 30th 2025

Matthew Lee, MD, details the improved disease-free survival outcomes with adjuvant alectinib in patients with ALK-positive NSCLC.

Dr Shields on the Evolving Role of Prophylactic Cranial Irradiation in SCLC

September 30th 2025

Misty D. Shields, MD, PhD, discusses the modern role for prophylactic cranial irradiation in extensive-stage SCLC management.

Integrating Biomarker Testing Into Early-Stage NSCLC Care

September 30th 2025

Panelists discuss how comprehensive biomarker testing is essential for all patients with early-stage non–small cell lung cancer (NSCLC), with thoracic specialists emphasizing the importance of testing primary tumor samples and lymph nodes to identify actionable mutations that guide treatment decisions and inform patients about their therapeutic journey, particularly as targeted therapies and immunotherapies continue to advance in early-stage and locally advanced disease settings.